The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.
The vision for a medical system that would eliminate experimentation with different drugs and where the physician would have tools at hand to deliver a precise treatment plan, is now a step closer to being achieved. The FDA, today, launched the beta version of precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools, to further their own research and support decisions when using next generation sequencing (NGS).
According to the website, the dynamic and rapidly growing community of precisionFDA includes:
· Genome test or software providers
· Standards-making bodies
· Pharmaceutical and biotechnology companies
· Healthcare providers
· Academic medical centers
· Researchers
· Patients
· FDA and other government agencies
In a blog describing the initiative, 2 of the architects of the tool Taha A. Kass-Hout, MD, MS, and Elaine Johanson, describe the initiative and its potential. This data-sharing platform will open up a world of opportunities for collaborations that will ultimately translate into information on a person’s health status, risk of disease, and possible responses to treatment, they write. Additionally, the platform will allow users to compare their results against previously validated reference results on genomic tests, as well as obtain feedback. To encourage data transparency, FDA plans to place the code for precisionFDA on the largest open source software repository, GitHub.
The Personalized Medicine Coalition (PMC) has applauded the FDA’s efforts. In a statement released today, Daryl Pritchard, PhD, vice president of science policy at PMC, said, “PrecisionFDA is an encouraging effort to engage the personalized medicine community in FDA's decision-making processes. We hope stakeholders will use it and participate in its continued development. We look forward to working with FDA as the agency continues to consider the implications of various approaches to NGS oversight.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More